Circulating insulin-like growth factor II and colorectal adenomas.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86663
Title:
Circulating insulin-like growth factor II and colorectal adenomas.
Authors:
Renehan, Andrew G; Painter, John E; O'Halloran, Domhnall J; Atkin, Wendy S; Potten, Christopher S; O'Dwyer, Sarah T; Shalet, Stephen M
Abstract:
Circulating insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) may be risk factors for the development of colorectal cancer. On the other hand, IGF-II and IGFBP-2 are overexpressed in colorectal carcinomas. These contrasting backgrounds led us to investigate the relationship between serum IGF-I, IGF-II, IGFBP-2, and IGFBP-3 and the presence of colorectal adenomas, known precursors of colorectal carcinoma, in 345 volunteers attending a screening flexible sigmoidoscopy trial (entry criteria: healthy, aged 55-64 yr). The most striking finding was an elevated mean serum IGF-II in individuals with adenomas (n = 52) compared with controls (mean difference, 139 ng/mL; 95% confidence intervals, 82, 196; P < 0.0001). Logistic regression adjusting for confounding factors confirmed the significant association between IGF-II and adenoma occurrence (P < 0.0001) and revealed an additional positive association with serum IGFBP-2 (P < 0.0001). However, there was no association found between either serum IGF-I and/or IGFBP-3 and the presence of adenomas. Additionally, in 31 individuals with adenomas in whom levels were determined pre- and postpolypectomy, there was a significant fall in mean IGF-II (P < 0.001) and IGFBP-2 (P < 0.001) after adenoma removal, but no difference in IGF-II and IGFBP-2 concentrations between repeated samples in 20 individuals without adenomas. Immunohistochemical studies demonstrated IGF-II expression in 83% of all adenomas, which contrasted with absent expression in normal colonic expression and hyperplastic polyps. This study has shown for the first time that serum IGF-II may be a tumor marker in individuals with colorectal adenomas. Further studies are needed to validate these relationships in larger populations, including individuals undergoing colonoscopy.
Affiliation:
Department of Surgery, Christie Hospital National Health Service Trust, Manchester, United Kingdom.
Citation:
Circulating insulin-like growth factor II and colorectal adenomas. 2000, 85 (9):3402-8 J. Clin. Endocrinol. Metab.
Journal:
The Journal of Clinical Endocrinology and Metabolism
Issue Date:
Sep-2000
URI:
http://hdl.handle.net/10541/86663
DOI:
10.1210/jc.85.9.3402
PubMed ID:
10999841
Type:
Article
Language:
en
ISSN:
0021-972X
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorRenehan, Andrew Gen
dc.contributor.authorPainter, John Een
dc.contributor.authorO'Halloran, Domhnall Jen
dc.contributor.authorAtkin, Wendy Sen
dc.contributor.authorPotten, Christopher Sen
dc.contributor.authorO'Dwyer, Sarah Ten
dc.contributor.authorShalet, Stephen Men
dc.date.accessioned2009-11-23T11:16:21Z-
dc.date.available2009-11-23T11:16:21Z-
dc.date.issued2000-09-
dc.identifier.citationCirculating insulin-like growth factor II and colorectal adenomas. 2000, 85 (9):3402-8 J. Clin. Endocrinol. Metab.en
dc.identifier.issn0021-972X-
dc.identifier.pmid10999841-
dc.identifier.doi10.1210/jc.85.9.3402-
dc.identifier.urihttp://hdl.handle.net/10541/86663-
dc.description.abstractCirculating insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) may be risk factors for the development of colorectal cancer. On the other hand, IGF-II and IGFBP-2 are overexpressed in colorectal carcinomas. These contrasting backgrounds led us to investigate the relationship between serum IGF-I, IGF-II, IGFBP-2, and IGFBP-3 and the presence of colorectal adenomas, known precursors of colorectal carcinoma, in 345 volunteers attending a screening flexible sigmoidoscopy trial (entry criteria: healthy, aged 55-64 yr). The most striking finding was an elevated mean serum IGF-II in individuals with adenomas (n = 52) compared with controls (mean difference, 139 ng/mL; 95% confidence intervals, 82, 196; P < 0.0001). Logistic regression adjusting for confounding factors confirmed the significant association between IGF-II and adenoma occurrence (P < 0.0001) and revealed an additional positive association with serum IGFBP-2 (P < 0.0001). However, there was no association found between either serum IGF-I and/or IGFBP-3 and the presence of adenomas. Additionally, in 31 individuals with adenomas in whom levels were determined pre- and postpolypectomy, there was a significant fall in mean IGF-II (P < 0.001) and IGFBP-2 (P < 0.001) after adenoma removal, but no difference in IGF-II and IGFBP-2 concentrations between repeated samples in 20 individuals without adenomas. Immunohistochemical studies demonstrated IGF-II expression in 83% of all adenomas, which contrasted with absent expression in normal colonic expression and hyperplastic polyps. This study has shown for the first time that serum IGF-II may be a tumor marker in individuals with colorectal adenomas. Further studies are needed to validate these relationships in larger populations, including individuals undergoing colonoscopy.en
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshAdenoma-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunohistochemistry-
dc.subject.meshInsulin-Like Growth Factor Binding Protein 2-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshInsulin-Like Growth Factor II-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshRegression Analysis-
dc.subject.meshSigmoidoscopy-
dc.subject.meshTumor Markers, Biological-
dc.titleCirculating insulin-like growth factor II and colorectal adenomas.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Christie Hospital National Health Service Trust, Manchester, United Kingdom.en
dc.identifier.journalThe Journal of Clinical Endocrinology and Metabolismen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.